Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?

Chakravarti, Anita; Chauhan, Mohit; Dogra, G. S.; Banerjee, Sayantan

doi:10.1016/j.bjid.2012.10.028

Cited by 26 publications

(22 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCV core-Ag testing has been shown to be valuable in detection of active HCV infection, HCV infection in seronegative hemodialysis patients, early treatment monitoring, and as a cost-effective alternative to nucleic acid technology for the identification of blood donors in the preseroconversion window. [10][11][12][13][14] The arrival of DAAs has reduced the need for pretreatment viral load measurement. Detection of HCV replication prior to therapy and its absence 12 weeks after end-oftherapy may be sufficient for diagnosis and monitoring of the treatment.…”

Section: Diagnosis Of Hcv Infectionmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

Section: Diagnosis Of Hcv Infectionmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…The core antigen was 32 positive samples of 42 real-time RT-PCR positive samples (76.1%) and 10 negative samples (23.8%), and real-time RT-PCR was more specific than HCV cAg assay as 30 samples were negative of 38 PCR negative samples 78.9% and 8 negative samples 21%. Chakravarti et al (2013) reported the sensitivity of HCVcAg assay was 92.86% when compared to HCV RNA in anti-HCV Ab negative cases, and the specificity was 100%. The positive and negative predictive values were 100% and 99.22% respectively.…”

Section: Discussionmentioning

confidence: 99%

Evaluation Of An Enzyme Immunoassay For Hepatitis C Virus Core Antigen As A Diagnostic Test For Detection Of Hepatitis C Virus Infection In Comparison To Real-Time RT-PCR

El-Kholy¹,

Kasem²,

Khalil³

et al. 2017

AJVS

View full text Add to dashboard Cite

Key words:HCV, ELISA, real-time RT-PCR, HCV core antigen Hepatitis C virus (HCV) is a global public health care problem. Diagnosis of HCV infection was mainly based on the detection of anti-HCV antibodies as a screening test with serum samples and detection of HCV RNA by using real-time RT-PCR, which considered as a golden standard test. In this study, we compared the HCV core antigen (HCV cAg) test with the HCV RNA assay for confirming anti-HCV results to determine whether the HCV cAg test may be used as an alternative confirmatory test to the HCV RNA test and to assess its diagnostic values by determining the specificity and sensitivity rates compared to the realtime RT-PCR test. Sera samples from 100 persons were analyzed by ELISA for anti-HCV and HCV core antigen and with the molecular HCV RNA assay as a confirmatory test. The diagnostic sensitivity, specificity, positive and negative predictive values of the HCV cAg assay compared to the HCV RNA test were 76.1%, 86.2%, 80%, and 82.5%, respectively. The HCV cAg levels showed a poor correlation with those from the HCV RNA quantification (r = 0.321, p= 0.079). In conclusion, the core antigen detection test can be more valuable in HCV diagnosis than anti-HCV antibodies but it cannot replace HCV RNA in confirmation of the diagnosis of HCV because the sensitivity of the HCV cAg detection assay is significantly lower than that of real-time RT-PCR based methods

show abstract

“…Because it has been established that viral load is relatively stable in the chronic phase of the infection, of these parameters, viral load seems to be more useful for the tailoring of treatment schedules and the monitoring of HCV replication during therapy. This dissimilarity also represents the variation of HCV infections in different geographical areas and different studies design [22,26].…”

Section: Discussionmentioning

confidence: 99%

Quantitation assay of hepatitis C virus RNA using real-time PCR technique

Taha¹,

Ali²,

Sabeer³

2017

Cihan Univ.-Erbil Sci. J.

View full text Add to dashboard Cite

Hepatitis C virus is a major cause of acute and chronic infections leading to fibrosis, cirrhosis, and hepatocellular carcinoma. A real-time PCR analysis has been employed successfully for both basic research and clinical applications. The ability to monitor the real-time progress of the amplification greatly improves the PCR-based quantitation of Hepatitis C virus RNA. The study was determine the viral load of hepatitis C virus RNA by real-time PCR technique and the influence of the gender on HCV viral load. The presence of HCV antibodies were assessed in clinically suspected HCV infection patients using commercial HCV Ab ELISA test kit, then all positive test were tested for detection and quantitative of HCV RNA by real-time PCR at Public Health Laboratory in Erbil, Iraq. Among 445 patients of HCV sero positive with ELISA screening test, RNA HCV was detected in 195(43.82%) patients by quantitative realtime PCR. Based on the distribution of viral load, 38.97% of patients had viral loads of 10 6 IU/ml, 0.51% had viral loads between 10 8 and 10 9 IU/mL, and 6.67% had 10 3 IU/ml.In conclusion, the highest rate of HCV was detected among sero positive males.

show abstract

Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?

Cited by 26 publications

References 16 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Evaluation Of An Enzyme Immunoassay For Hepatitis C Virus Core Antigen As A Diagnostic Test For Detection Of Hepatitis C Virus Infection In Comparison To Real-Time RT-PCR

Quantitation assay of hepatitis C virus RNA using real-time PCR technique

Contact Info

Product

Resources

About